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500Objective:Dexmedetomidine, an a-2a adrenergic agonist, given pre- and postoperatively was previously shown
to attenuate neuronal injury in a murine model of spinal cord ischemia-reperfusion. In the brain, a-2 agonists
have been shown to induce the phosphorylation of cyclic AMP response-element binding protein (CREB), a
transcription factor necessary for neuron survival. We hypothesized that the a-2a adrenergic agonist given
preoperatively increases CREB-mediated neuroprotective proteins, attenuating neuronal injury and cytoarchi-
tectural decay.
Methods: Mice (ie, C57BL/6 mice) underwent 5 minutes of aortic occlusion via median sternotomy.
Mice received 25 mg/kg dexmedetomidine or equivalent normal saline at 24 hours, 12 hours, and 30 minutes
preoperatively. Functional outcomes were recorded at 6 to 48 hours postoperatively when spinal cords were
removed for histologic analysis. Spinal cords were examined for protein kinase B, CREB, B-cell lymphoma
2, and brain-derived neurotrophic factor following treatment alone or ischemia-reperfusion surgery.
Results: Following aortic occlusion, mice in the treatment group had preserved neurologic function at all time
points (P<.05). Histologic analysis showed preserved cytoarchitecture and decreased neuronal injury in the
treatment group when compared with ischemic controls. Additionally, analysis of spinal cord homogenate
following surgery and pretreatment revealed a significant (P<.05) increase in B-cell lymphoma 2 and brain-
derived neurotrophic factor expression and protein kinase B and CREB phosphorylation with a-2a adrenergic
agonist pretreatment.
Conclusions: Pretreatment with the a-2a agonist dexmedetomidine preserved neurologic function and attenu-
ated neuronal injury following thoracic aortic occlusion in mice. This relationship was associated with an
increased phosphorylation of protein kinase B and CREB and subsequent up-regulation of antiapoptotic factor
B-cell lymphoma 2 and brain-derived neurotrophic factor. Thus, a-2a receptor agonism-induced CREB phos-
phorylation and contributes to dexmedetomidine’s protective mechanism in the spinal cord following ischemia.
(J Thorac Cardiovasc Surg 2014;147:500-7)The ischemic insult to the spinal cord during thoracoabdo-
minal aortic interventions continues to have devastating
consequences in up to one fifth of high-risk patients.1
Surgical adjuncts such as hypothermic circulatory arrest
and cerebrospinal fluid drainage have reduced the incidence
of the complication; however, implementation of these
measures has only been met with a partial reduction of
postoperative paraplegia.2
Ischemia-reperfusion (IR) injury is complex and poorly
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The Journal of Thoracic and Cardiovascular Surgischemia and coupled with their inability to regenerate, spi-
nal cord IR is a significant threat to patients. Pharmacologic
adjuncts that increase ischemic tolerance by neurons would
serve as an ideal adjunct to further reduce the risk of this
complication.
The neuroprotective effects of a-2 receptor agonists have
been studied for more than 20 years3; however, their
mechanisms of protection from ischemia-reperfusion
remain unknown. In cerebral neurons, clonidine and other
a-2 agonists have been shown to promote phosphorylation
of neuroprotective pathways.4 One such pathway converges
at cyclic AMP response-element binding protein
(CREB).5,6 CREB is a transcription factor that is critical
for neuron survival after ischemia supporting its role in
the induction of ischemic tolerance.7 Among other
functions, CREB induces expression of prosurvival proteins
such as B-cell lymphoma 2 (BCL-2),8 brain derived
neurotrophic factor (BDNF),9,10 and a variety of free
radical scavengers.11,12
Dexmedetomidine is a newer and more specific a-2a
agonist. It is commonly used in operating rooms and inery c January 2014
Abbreviations and Acronyms
BCL-2 ¼ B-cell lymphoma 2
BDNF ¼ brain-derived neurotrophic factor
CREB ¼ cyclic AMP response-element binding
protein
IR ¼ ischemia-reperfusion
PBS ¼ phosphate buffered saline
Bell et al Evolving Technology/Basic Scienceintensive care units. It has gained widespread attention for
its neuroprotective properties in the brain.13,14 We
therefore postulated that it may have neuroprotective
properties in the spinal cord. We hypothesized that
pretreatment with dexmedetomidine will preserve
neurologic function and neuron viability following
thoracic aortic occlusion by promoting ischemic tolerance
in the spinal cord through an induction of CREB-
mediated neuroprotective proteins.
METHODS
Animal Procedures
The Animal Care and Use Committee at the University of Colorado at
Denver Health Sciences Center approved all experiments, and this investi-
gation conformed to the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (www.nap.edu/catalog/5140.
html). Male C57BL/6mice between ages 10 and 20 weeks were used for all
experiments.
Aortic Crossclamping: IR Surgery
Mice were anesthetized using 2% isoflurane and placed in the supine
position. Surgery was performed under normothermic conditions. The
core body temperature was maintained at 36.5C  0.5C using a rectal
temperature probe and automatic temperature adjusting bed (Vestavia
Scientific, Birmingham, Ala). The aortic arch was exposed using a cervico-
thoracic approach as previously described.15 Disruption of arterial flow to
the spinal cord was achieved by placing vascular clamps on the aortic
arch distal to the left common carotid artery and the subclavian artery
for 5 minutes. To confirm at least 90% reduction in distal flow, a laser
Doppler blood flow monitor (Moor Instruments, Devon, United Kingdom)
was placed over the left femoral artery.
Medication Administration
Mice in the treatment group received intraperitoneal injections of
25 mg/kg dexmedetomidine (n ¼ 8) based on previous studies13 or normal
saline (n¼ 8) at 24 hours, 12 hours, and 30minutes before IR. Additionally,
3 mice underwent sham surgery with sternotomy and dissection of the aortaFIGURE 1. Graphic representation of the study design. AKT, Protein kinase
lymphoma 2; BDNF, brain-derived neurotrophic factor; Dex, dexmedetomidine
The Journal of Thoracic and Caand subclavian artery with no occlusion. To compare effects of medication
administration alone, 4 treated mice and 4 mice given normal saline
injections at time points above had spinal cords removed for protein and
messenger RNA studies without IR surgery.
Functional Scores
The Basso Mouse Scale for locomotion,16 which ranges from a score of
0 for complete paraplegia to a score of 9 for normal function, was used to
quantify hind-limb function in mice after ischemia. Function was scored at
12, 24, 36, and 48 hours after reperfusion.
Histologic Analysis
After 48 hours of reperfusion, the animals were sacrificed. The vertebral
columnwas removed en bloc from T8-L3. Spinal cords were removed from
the vertebral column by injection of phosphate buffered saline (PBS) (pH
7.4) into the spinal column. Spinal cords were then transferred to 4%
formalin where they remained for at least 24 hours before paraffin
embedding, sectioning, and hemotoxylin and eosin staining.
Quantification of Neuron Degeneration
Spinal cords were placed into paraffin block following 48 hours of
reperfusion. Sections 5-mm thick were placed on poly-lysine slides.
Paraffin was removed by placing slides in 100% xylene followed by
washes with 100% ethanol and 70% ethanol deionized water. Slides
were then blocked with a solution of 0.06% potassium permanganate
(Sigma Aldrich, St Louis, Mo) and stained with Flouro Jade-B stain
(EDM Millipore, Billerica, Mass), a marker for neuron degeneration.17
Stock solution was diluted in 0.1% acetic acid a final concentration of
0.0004% Flouro Jade-B and applied for 30 minutes. Slides were then
rinsed in deionized water and placed in the dark to air-dry overnight.
Once dry, 100% xylene was applied and slides were mounted with DPX
(Sigma Aldrich, St Louis, Mo). Quantification of degenerating neurons
was performed by a blinded observer and the number and expressed as
number of degenerating neurons per high power field.
Immunoblotting
Spinal cords were removed following pretreatment or IR surgery
(Figure 1). Protein extracts were obtained using M-lysis buffer (Roche, In-
dianapolis, Ind) per themanufacturer’s instructions and were placed in a 4X
Laemmmli buffer with b-mercaptoethanol and boiled for 10 minutes at
100C, loaded into a 15-well 4% to 20% gradient-ready gels (Bio-Rad,
Hercules, Calif), and run at 160 V for 450 minutes. The gels were
transferred to nitrocellulose membranes at 100 V for 60 minutes and
then cross-linked using a UV Stratalinker (Stratagene, La Jolla, Calif).
The membranes were blocked in 5% dry milk in 0.1% Tween with PBS,
and rinsed 3 times in 0.1% Tween with PBS. The blocked membranes
were incubated with primary antibodies overnight at 4C (5% bovine
serum albumin in 0.1% Tween with PBS). The membranes were washed
in 0.1% Tween with PBS 3 times and incubated in appropriate horseradish
peroxidase-conjugated secondary antibodies diluted to 1:5000 in 5%B; CREB, cyclic AMP response-element binding protein; BCL2, B-cell
.
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FIGURE 2. Following ischemia-reperfusion (IR) surgery with 5 minutes
of aortic occlusion a significant functional deficit in hind-limb function was
observed in all mice. Twenty-four hours of pretreatment with dexmedeto-
midine (IRþDex) resulted in significantly higher neurologic function at all
time points postoperatively. Error bars represent standard error of the
mean. *P<.05.
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ature. SuperSignal West Dura Chemiluminescent Substrate for HRP
(Thermo Scientific, Rockford, Ill) was used for 5 minutes; membranes
were visualized using a Chemidoc Hi Sensitivity scanner (BioRad, Hercu-
les, Calif). Mean density values of bands were quantified by QuantityOne
software (BioRad, Hercules, Calif).
Quantitative Polymerase Chain Reaction
Measurements of BCL-2 and BDNF transcripts from treated and
untreated spinal tissue without undergoing IR surgery were performed.
Total RNA was isolated using the RNAqueous-4 PCR kit (Ambion,
Austin, Tex) per the manufacturer’s instructions. Real-time polymerase
chain reactions using iQ mastermix (Bio-Rad, Hercules, Calif) on
Bio-Rad CFX detection system (Hercules, Calif) were performed in
duplicate using 50 ng complementary DNA. FAM-labeled probe/primer
sets used to detect BCL-2 (Mm00477631_m1) and BDNF
(Mm04230607_s1) were synthesized by Invitrogen (Grand Island,
NY). The housekeeping gene b-actin (Mm00607939_s1) was also
assayed for each sample using 5 ng complementary DNA. Cycle
parameters used 95C for 3 minutes followed by 40 cycles of 95C
for 15 seconds and 60C for 1 minute. Expression levels were calculated
using the delta-delta Ct method relative to b-actin.FIGURE 3. Mice undergoing ischemia-reperfusion surgery had a significant dis
normal-appearing anterior horn neurons and increased vacuolization was obs
treatment (IRþDEX) groups.
502 The Journal of Thoracic and Cardiovascular SurgStatistical Analysis
Statistical analysis was performed using repeated measures and the
Kruskal-Wallis nonparametric analysis of variance with Bonferroni/Dunn
post-hoc test using StatView (SAS Institute Inc, Cary, NC). Two-way
analysis was performed using unpaired t test. Continuous data are
presented as mean  standard error. Continuous data are represented as
mean  standard deviation.
RESULTS
Functional Outcomes
Mice in the sham group had no observable functional
deficit at any time point in the postoperative period.
Ischemia with 5 minutes of aortic occlusion produced a
significant functional deficit in all mice. Twenty-four hours
of pretreatment with dexmedetomidine resulted in a
significant preservation of neurologic function (P<.05) at
all time points postoperatively (Figure 2).
Histologic and Neurocytoarchitectural Outcomes
All mice undergoing IR surgery had a disruption of
anterior horn cytoarchitecture when compared with sham
mice. Ischemic control mice demonstrated a more
pronounced disruption of cytoarchitcture, a reduction of
normal-appearing anterior horn neurons and increased
vacuolization when compared with the sham and treatment
groups (Figure 3). Anterior horns of spinal cords were
stained with Flouro Jade-B, a marker of neuronal injury,
and quantified by a blinded observer (Figure 4). All mice
undergoing IR surgery had a significant increase in Flouro
Jade–B-positive neurons. Mice treated with dexmedetomi-
dine had a significant reduction in Flouro Jade–B-positive
neurons when compared with ischemic controls.
Pretreatment and Survival Signaling
To examine spinal cord cellular signaling at time point 0,
mice received identical pretreatment with dexmedetomi-
dine (n ¼ 4) or 0.9% normal saline (n ¼ 4) and had spinal
cords removed with no surgery. Spinal cord homogenates
were analyzed for AKT and CREB phosphorylation.
Following pretreatment there was a robust and significant
(P < .05) increase in AKT and CREB phosphorylationruption of cytoarchitecturewhen compared with shammice. A reduction of
erved in ischemic control mice (IR) when compared with the sham and
ery c January 2014
FIGURE 4. All mice undergoing ischemia-reperfusion surgery had a significant increase in Flouro Jade–B (EDM Millipore, Billerica, Mass)-positive
neurons. Mice treated with dexmedetomidine (IRþDEX) had a significant reduction in neuronal injury when compared with ischemic controls (IR).
Error bars represent standard error of the mean. *P<.001. þþP<.0001.
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phosphorylation resulted in a subsequent production of
neuroprotective proteins with dexmedetomidine treatment
alone, spinal cord tissuewas tested by quantitative polymer-
ase chain reaction for production of BCL-2 and BDNF.
Pretreatment with dexmedetomidine resulted in a signifi-
cant up-regulation of BCL-2 and BNDF at time point
0 when compared with vehicle controls (treated with
0.9% normal saline) (Figure 6, A). At the duration of the
experiment spinal cord homogenate was examined for the
presence of CREB-mediated proteins BCL-2 and BDNF.
Dexmedetomidine treatment resulted in statistically
significant elevations in both BCL-2 and BDNF expression
following IR surgery (Figure 6, B and C).
DISCUSSION
Paraplegia remains the most-feared complication of
aortic surgery. The results of our study demonstrate that
treatment with the a-2a agonist dexmedetomidine before
aortic occlusion provided functional protection. This
functional protection was associated with histologic evi-
dence of preservation of the spinal cord cytoarchitecture,
diminished marker of neuronal injury (Flouro Jade-B),
activation of neuron signaling pathways that are important
for neuron survival (protein kinase B and CREB
signaling), and increased production of CREB-mediated
proteins linked to neuron survival (BCL-2 and BDNF).The Journal of Thoracic and CaThese data suggest that pretreatment with dexmedetomi-
dine may offer a strategy for spinal cord protection during
aortic surgery.
Using a murine model of delayed paraplegia, our
laboratory has previously shown that dexmedetomidine
can produce significant neuroprotection in the spinal cord
when given before and after thoracic aortic occlusion.18
The murine model used in our study was designed to mimic
the early paraplegia seen following aortic surgery. It is
widely held that such early paraplegia results from a severe
metabolic injury to the spinal cord neurons during
ischemia.19 Therefore, the model used in our study differs
from that which our group has previously used in 2 impor-
tant ways. First, a longer ischemic time was employed. In
our model this produced an injury that more closely resem-
bled the clinical entity of immediate paraplegia.12 Second,
no postoperative treatment was included to focus on the
potential actions of pretreatment with an a-2a agonist.
The cumulative injuries of ischemia and reperfusion are
complex, and those of reperfusion are known to exacerbate
those of ischemia. In our study, the a-2a agonist was admin-
istered before ischemia. A limitation of our study is that it is
not possible to determine if the beneficial effects of
dexmedetomidine were due to attenuation of the ischemic
injury, the reperfusion injury, or both. Nonetheless,
when given before ischemia, dexmedetomidine exhibited
functional protection against IR.rdiovascular Surgery c Volume 147, Number 1 503
FIGURE 5. Spinal cord cellular signaling of neuroprotective pathways at time point 0. Mice receiving pretreatment alone with dexmedetomidine (Dex)
had significantly higher phosphorylation of prosurvival protein kinase (pAKT) (P ¼ .005) and prosurvival cyclic AMP response-element binding
protein (pCREB) (P ¼ .004) in all patients P values of<0.05 are denoted by ‘‘*’’ when compared with mice receiving normal saline (NS) 0.9%. *P<
.05. Error bars represent standard error of the mean. tAKT, Total protein kinase B; tCREB, total cyclic amp response element binding protein.
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cant spinal cord injury immediately following surgery and
throughout the duration of the experiment in control mice.
In comparison, mice in the dexmedetomidine-treatment
group had significantly preserved hind-limb function
when compared with ischemic control at all time points
through the duration of the experiment. Though the extent
of neuroprotection was not as complete as we have seen
with shorter durations of ischemic times18; however, statis-
tical significance was still obtained. These findings could be
secondary to either the increased ischemic time or absence
of postoperative dexmedetomidine administration.
Our second purpose was to determine if dexmedetomi-
dine pretreatment resulted in activation neuronal prosurvival
pathways. This was accomplished by examining spinal
cords at time point 0 for induction of neuroprotective path-
ways related to the promotion of ischemic tolerance, namely
protein kinaseB20 andCREB.7Dexmedetomidine treatment
resulted in a significant increase in phosphorylation of both504 The Journal of Thoracic and Cardiovascular Surgprotein kinase B and protein kinase B’s downstream target
CREB.
CREB is a transcription factor considered to be critical in
programmed cell survival, as opposed to death.21 Addition-
ally, it is widely accepted that CREB phosphorylation is a
necessary component of ischemic preconditioning.22 In
stroke models, CREB-mediated induction of protective
pathways significantly preserved neuronal survival.6 More
importantly, studies on global ischemia have intimated
that robust increases in CREB phosphorylation in neurons
have a substantial affect on ischemic tolerance when
compared with ischemia-vulnerable neurons.23,24
The protective effects of CREB likely results from the
induction of neuroprotective proteins. Both BCL-2 and
BDNF have been shown to be induced by CREB.8,9 BCL-
2 is a potent inhibitor of neuron death from apoptosis and
necrosis.25 Following ischemia, BCL-2 prevents mitochon-
drial membrane permeability, inhibiting cytochrome C
release.26 Studies of transient brain ischemia demonstratedery c January 2014
FIGURE 6. A, Quantitative polymerase chain reaction for production of B-cell lymphoma 2 (BCL-2) and brain-derived neurotrophic factor (BDNF)
transcripts was performed. Pretreatment with dexmedetomidine resulted in a significant up-regulation of BCL-2 (P  .0001) and BNDF (P ¼ .040)
messenger RNA expression at time point 0. B, Expression of cyclic AMP response-element binding-mediated neuroprotective proteins BCL-2 and
BDNF was examined 48 hours following ischemia-reperfusion (IR) surgery and compared with housekeeping protein b-actin. Significant elevations in
both BCL-2 (P ¼ .004) and BDNF (P ¼ .0035) expression following IR surgery were observed with dexmedetomidine pretreatment (IRþDex) when
compared with ischemic controls (IR) 48 hours following surgery. C, Representative immunoblot following IR. Error bars represent standard error of
the mean. DDCT, Expression.
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outcomes.27 Moreover, similar overexpression of BCL-2 in
the spinal cord suppressed motor functional deficits
following traumatic injury.28
Another protein, BDNF, is a member of the neurotrophin
family. Neurotrophins are a family of proteins that can regu-
late the survival, development, and function of neurons.21
BDNF may have a role in neuroplasticity related to
improved long-term outcomes in stroke models. It has
also been associated with inflammatory reduction and
reduction of apoptosis.29 No matter the mechanism,
BDNF overexpression has been shown to induce a critical
reduction of neuronal injury following cerebral ischemia.30
Pretreatment with dexmedetomidine resulted in an
increased expression of messenger RNA from the CREB-
mediated proteins BCL-2 and BDNF. Following IR, the
levels of these proteins were also significantly elevated in
the treated mice with preserved function providing further
evidence of neuroprotection.
The results of our study suggest that dexmedetomidine
may be a clinical accessible tool to be used in aortic surgery.
Unlike other agents with reported neuroprotective proper-
ties, dexmedetomidine is commonly used clinically inThe Journal of Thoracic and Caboth operating rooms and intensive care units. Additionally,
dexmedetomidine does not influence evoked potential as
some of the anesthetics can.31 Dexmedetomidine can
readily be added as an adjunct during high-risk aortic
interventions.
Our study is not without limitations. First, in animal
models it is difficult to distinguish the injuries resulting
from the ischemic and reperfusion insults. Second, although
the study provides a mechanistic explanation for dexmede-
tomidine mechanism of action, additional studies using
CREB inhibitors in different central nervous system cell lin-
eages will provide further information for dexmedetomi-
dine’s neuroprotective effects.
CONCLUSIONS
Pretreatment with the a-2a agonist dexmedetomidine
preserves neurologic function and attenuated neuronal
injury following thoracic aortic occlusion in mice. The
observed neuroprotection was associated with CREB
-phosphorylation and production of CREB’s downstream
neuroprotective targets BCL-2 and BDNF. Dexmedetomi-
dine may be another adjunct for reducing the devastating
complication of paraplegia in high-risk aortic interventions.rdiovascular Surgery c Volume 147, Number 1 505
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Discussion
Dr John S. Ikonomidis (Charleston, SC). I would like to
congratulate Dr Bell for a very nice presentation and thank him
for sending me his slides and his presentation in advance. I have
a few questions. The first relates to the model. Conceptually
speaking in humans, 5 minutes of aortic occlusion really would
not be expected to produce the kind of spinal cord damage that
you saw in this model, so please explain briefly why you think
there are differences between mice and humans and put that in
the context of the potential clinical relevance of this study.
Dr Bell. I think 1 of the main differences within the spinal cords
is that the murine metabolic rate is much higher, so we are able to
see this injury under normothermic conditions at 5 minutes
compared with 45 minutes.
Dr Ikonomidis.While we are on the subject of hemodynamics
and heart rate, did you measure blood pressure during this study
and can you comment on blood pressure between the 2 groups?
Dr Bell.We previously looked at blood pressure with dexmede-
tomidine treatment before and after surgery, and did not see a dif-
ference in mice that were under the influence of isoflurane
anesthesia.
Dr Ikonomidis.What was the justification for the use of 25 mg
dexmedetomidine?
Dr Bell. It was done based on previous studies of neuroprotec-
tion with the middle cerebral artery occlusion model. It was seen
that the neuroprotective effects peaked at 25 mg/kg. This was
also a dose that caused no sedation and, we think, more correlated
with an anxiolytic dose.
Dr Ikonomidis. So if I were to give it to human patients, what
would be the intravenous dose?
Dr Bell. That is a great question. We haven’t been able to quan-
tify the exact amount for human patients. The intravenous dose is 1
mg/kg loaded over 10 minutes and then 0.5 mg/kg basal dosing.
Dr Ikonomidis. It strikes me that a lot of the data you presented
here are, to a large extent, associative, and I was wondering if you
have done specific mechanistic studies. For example, do you have
a cyclic AMP response-element binding (CREB) protein knockout
mouse in which you can abrogate spinal cord damage, or have you
done similar studies?
Dr Bell. CREB knockout mice are nonviable, but we have
developed our in vitro model, and we are able to grow these neu-
rons in a dish. We will be able to then use antibodies as well asery c January 2014
Bell et al Evolving Technology/Basic Sciencenucleotide inhibitors that we can further study to be able to nail
down that mechanism. These studies are going on currently.
Dr Ikonomidis. It is interesting that this model causes both
initial and delayed neurologic damage, so it mimics initial para-
plegia but also delayed paraplegia, and they both seem to be in-
hibited by dexmedetomidine. Can you comment on the potential
mechanisms? Are they similar or the same?
Dr Bell. In this experiment we chose 5 minutes because we
wanted to look at the initial ischemic insult and be able to associate
the observed injury with the ischemic insult. We, as well as others,
have looked at microglial activation and their contributions to de-
layed paralysis. Dexmedetomidine also has some anti-inflamma-
tory effects on microglial in vitro that could also contribute to
these findings. We did not treat them postoperatively because we
did not want to modify the inflammatory cascade in any way.
Dr Ikonomidis.Youmeasured protein kinase B (AKT) levels in
this study; an abundance of AKT. Did you look at any of its acti-
vating surrogates, such as phosphoinositide 3-kinase?
Dr Bell.No, we have not looked at that. It is something wewant
to do in vitro and to tie in more closely to the a-2 receptor, and I
think in vitro we could more easily do that.
Dr Ikonomidis. Thank you very much.
Dr Scott A. LeMaire (Houston, Tex). Dr Ikonomidis touched
on this, but my question relates to the potential use for this agonistThe Journal of Thoracic and Cafor not only treating acute injury we see early in the operating
room but also delayed injury. How long do the cellular effects of
this agonist persist? Do you have any data related to how long
the protective effects might last?
Dr Bell.Wewant to carry it out further in our murine model and
look at some of the chronic changes. We have observed that de-
layed paraplegia consistently occurs at 36 to 48 hours. We have
seen protection against delayed paraplegia as well when we
post-treated mice at reperfusion in a previous study. One of the po-
tential benefits of this drug is that you can keep a high-risk patient,
maybe an Extent 2 patient, in an intensive care unit on this drug
even when they are extubated on an anxiolytic dosing regimen.
Dr Pirooz Eghtesady (St Louis, Mo). I have a question related
to the 24-hour pretreatment. How did you come up with 24 hours
as opposed to 12 hours or a week, and howwould you translate that
to the clinical setting?
Dr Bell. We chose the pretreatment interval based on previous
models of ischemic preconditioning that showed a maximal effect
when the initial surgery of the sublethal ischemia was performed at
24 hours. We also believed that this interval would give us an
adequate time period for the expression of neuroprotective pro-
teins. In the clinical setting I think it would not be out of the ques-
tion to admit a patient the day before for an infusion of
dexmedetomidine at an anxiolytic dose.rdiovascular Surgery c Volume 147, Number 1 507
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